- Volatility is at a recent 2 week high. A high volatility of stock movement indicates uncertainty.
- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
The United Kingdom’s use of genomic sequencing to identify a more infectious strain of SARS-COV-2 has largely served as a wake-up call for inadequate use of the technology in the U.S.
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
Biotech stocks were huge winners for investors last year, with some seeing 1,000% gains. If you're looking for a stock in this sector to add to your portfolio, Amgen (NASDAQ: AMGN), Trillium Therapeutics (NASDAQ: TRIL), and Illumina (NASDAQ: ILMN) are solid biotech choices for this month. Amgen, founded in 1980, is one of the older, larger biotech companies in the world.
Myriad Genetics (MYGN) partners with Illumina to expand the access as well as extend the reach of myChoice CDx through its services offering in the international market.
A leader in bringing down the costs of genetic sequencing sees opportunities for better diagnostics used to screen for cancers.
Illumina, Inc. (NASDAQ: ILMN) is transforming genomic data bottlenecks into catalysts with the launch of Illumina Connected Analytics (ICA). This new and integrated bioinformatics solution provides a comprehensive, private, cloud-based data platform that empowers customers to manage, analyze, and explore large volumes of multi-omic data in a secure, scalable, and flexible environment.
With genetic sequencing at the forefront of precision medicine, Illumina (NASDAQ: ILMN) is pleased to announce a portfolio of new and expanded oncology partnerships that further the company’s commitment to develop standardized, globally distributable tools for precision oncology.